Investor Overview
Adverum is a clinical-stage ocular gene therapy pioneer optimizing its next generation proprietary AAV vector as a broadly enabling targeted delivery platform. Our novel gene therapy candidate, ADVM-022, has the potential to offer durable treatment effects with most patients free of supplemental injections after a single, in-office intravitreal injection for wet age-related macular degeneration. Our AAV vector manufacturing process, based on the Baculovirus Expression Vector System (BEVS) used in numerous FDA- and EMA-approved products, is well-suited to produce large quantities of AAVs. Adverum is primed to develop, deliver, and drive future access to ADVM-022 for vision-threatening, VEGF-driven ocular disease.
Webcasts
Justo Inceptos Nibh Sit Etiam
Maecenas sed diam eget risus varius blandit sit amet non magna. Nullam id dolor id nibh ultricies vehicula ut id elit. Nulla vitae elit libero, a pharetra augue. Maecenas sed diam eget risus varius blandit sit amet non magna. Sed posuere consectetur est at lobortis. Nullam id dolor id nibh. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Donec ullamcorper nulla non metus auctor fringilla. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Donec id elit non mi porta gravida at eget metus.
Nullam id dolor id nibh ultricies vehicula ut id elit. Maecenas faucibus mollis interdum. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam id dolor id nibh ultricies vehicula ut id elit..
Contact Us
Financial Information
| Filing Date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 08/15/120 | S3 | Simplified registration form | Registration Statements | |
| 08/03/20 | 4/A | Simplified registration form | 3,4,5 | |
| 07/03/20 | 8-K | Report of unscheduled material events or corporate event | Current Reports | |
| 06/03/20 | 4 | Statement of changes in beneficial ownership securities | 3,4,5 |